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The presence of cytomegalovirus (CMV) 
gene products in glioblastoma multiforme 
(GBM) was first documented in 2002.1 
This finding was significant for at least 2 
reasons. First, the influence of viruses in 
the biology of cancer cells has been well 
described in other malignancies, such as 
cervical cancer and Kaposi’s sarcoma. 
Thus, the identification of CMV prod-
ucts in GBM lesions opened the possibil-
ity that CMV would promote malignant 
transformation and/or tumor progres-
sion. Second, in spite of standard of care 
therapy, GBM, which represents the most 
common and aggressive form of glioma, is 
associated with poor prognosis. Promising 
progresses toward an improved clinical 
management of glioma patients have been 
made with the advent of targeted thera-
pies, including gene delivery approaches, 
angiogenesis inhibitors, oncolytic viruses, 
and various immunotherapeutic regimens. 
The observation that CMV selectively 
infects glioma cells identifies another 
means by which GBM may be targeted 
with biological anticancer agents.2
By introducing the concept of onco-
modulation, Michaelis, Cinatl, and col-
leagues have provided a framework to the 
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Over the last decade, cytomegalovirus (CMV) has been suggested to promote the development of glioblastoma 
multiforme (GBM). recent evidence demonstrates that CMV contributes to the progression of GBM in the context of 
oncosuppressor gene mutations. this finding provides further insights into the mechanisms whereby CMV exacerbates 
the malignancy of GBM.
elucidation of the active role played by CMV 
in tumor progression.3 Oncomodulation 
is a process whereby CMV may infect 
cancer cells, hence affecting their func-
tions, without being directly involved in 
malignant transformation. In this setting, 
neoplastic cells provide the molecular and 
genetic milieu whereby disturbances in 
tumor suppressors, transcription factors, 
and signal transduction pathways allow 
CMV to exert an oncomodulatory effect.
Price et al. have discovered some of 
the oncomodulatory effects of CMV in 
the setting of oncosuppressor gene muta-
tions.4,5 An initial study demonstrated 
that Trp53+/− mice infected perinatally 
with murine CMV (MCMV) developed 
rhabdomyosarcoma (RMS) at an ear-
lier age and exhibited a shorter survival 
than control animals. Similar to human 
RMS, these murine tumors were found to 
express CMV proteins including pp65 and 
immediate-early 1 (IE-1). More recently, 2 
distinct mouse models of oncosuppressor 
mutations commonly associated with gli-
oma were employed to determine the effect 
of perinatal MCMV infection on tumor 
progression and overall survival. In par-
ticular, GFAP-cre:Nf1loxP/+:Trp53+/− Mut3 
mice and a syngeneic orthotopic model 
in which Nf1:Trp53:Pten mutated GBM 
cells were injected into the striatum of 
wild-type mice were used. Mut3 mice 
spontaneously develop high-grade astro-
cytomas with near-to-complete pene-
trance by adulthood. The localization of 
MCMV to malignant cells was confirmed 
and glioma-associated deaths were scored 
in survival analyses. In both these models, 
MCMV-infected mice showed an approx-
imate decrease of 20% in cancer-related 
survival as compared with mock-infected 
animals.
The activation of signal transducer and 
activator of transcription 3 (STAT3) was 
identified as a potential molecular mecha-
nism underpinning the decrease in sur-
vival of MCMV-infected mice, although 
it is possible that other, hitherto uniden-
tified, mechanisms might be operational. 
An increase in STAT3 phosphorylation 
was detected in vivo, both in MCMV-
infected Mut3 neural stem cells before 
tumor onset and in orthotopic GBM cells 
4 wk after inoculation in wild-type mice. 
This was associated with an increase in 
proliferating cell nuclear antigen (PCNA) 
positivity, probably representing the 
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Figure 1. Mechanisms of StAt3 activation by CMV. Cytomegalovirus (CMV) can activate signal transducer and activator of transcription 3 (StAt3) in 
glioblastoma multiforme (GBM) cells by 3 different mechanisms. CMV-infected cells secrete increased levels of interleukin-6 (IL-6), stimulating signal 
transduction via the IL-6 receptor (IL6r)-StAt3 axis.8 uS28 is a CMV-encoded constitutively active chemokine receptor that is capable of activating 
StAt3.9 the CMV virion can activate StAt3 via platelet-derived growth factor receptor α chain (PDGFrα), presumably by means of the viral surface 
glycoprotein B.10 the combination of StAt3 activation and oncosuppressor gene loss significantly exacerbates the malignancy of GBM cells.
proliferative effect that STAT3 activation 
has on GBM cells.6 Human GBM tumor-
spheres derived from patient tumor speci-
mens revealed a similar increase in STAT3 
phosphorylation following in vitro infec-
tion with HCMV. This finding correlated 
with increased tumorsphere size and cel-
lularity, in comparison to mock-infected 
control tumorspheres. In this setting, 
STAT3 inhibition successfully abolished 
the proliferative advantage caused by 
HCMV infection, indicating that the 
activation of STAT3 is involved in the 
oncomodulatory effects of CMV on both 
murine and human GBM.
This study contains the first in vivo 
data demonstrating the effects of MCMV 
on murine GBM-related death in the set-
ting of oncosuppressor gene mutations. 
Genomics analyses of human GBM sam-
ples revealed that the murine models that 
we employed bear mutations that affect 
the core signal transduction pathways 
most commonly mutated in the course of 
GBM. The genes coding for phosphatase 
and tensin homolog (PTEN ) and neuro-
fibromin 1 (NF1) are mutated or deleted 
in 36% and 18% of GBM cases, respec-
tively, and play an essential role as negative 
regulators of the signal transduction path-
way involving receptor tyrosine kinases 
(RTKs), RAS, and phosphoinositide-
3-kinase (PI3K), which is hyperactivated 
(hence delivering mitogenic and antiapop-
totic signals) in 88% of GBM patients. 
The TP53 oncosuppressive pathway is 
disrupted in 87% of GBM cases and is 
essential for cell cycle arrest and the ini-
tiation of apoptotic cell death in response 
to both intracellular and extracellular 
stress conditions.7 It is therefore likely 
that the molecular environment generated 
by genetic manipulations employed in 
this study is representative of the condi-
tions encountered during the infection of 
human GBMs by HCMV.
The role of STAT3 in the pathogenesis 
of GBM has gained significant attention 
over last several years.6 In particular, the 
aberrant activation of STAT3 has been 
shown to induce cell cycle progression, 
angiogenesis, and immune evasion. CMV 
can activate STAT3 by several mecha-
nisms (Fig. 1). Thus, US28, a CMV-
encoded chemokine receptor, has been 
shown to convey proliferative signals via 
the interleukin-6 (IL-6)-STAT3 pathway.8 
HCMV-infected GBM cells are known to 
secrete increased levels of IL-6 and express 
high levels of US-28.9 The activation of the 
platelet-derived growth factor receptor α 
chain (PDGFRα) is a required for produc-
tive CMV infection.10 The gene coding for 
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PDFGRα is commonly amplified in GBM 
patients, which may ultimately explain 
both the tropism of HCMV for GBM cells 
and the pronounced HCMV-mediated 
STAT3 hyperactivation.
The results of Price et al. lend sup-
port to the notion that the cellular and 
molecular alterations induced by CMV 
in combination with pathogenetic defects 
in core signal transduction pathways 
increase the malignancy of GBM cells 
much more than either of these processes 
alone. Whether HCMV constitutes an 
effective target for the treatment of GBM 
patients remains an open question. The 
hope is that a deeper understanding of the 
oncomodulatory effects of CMV on GBM 
will allow for the delineation of novel 
therapeutic strategies against this aggres-
sive malignancy.
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